Johnny Mahlangu

An evaluation of denecimig for bleeding prophylaxis in hemophilia A

Introduction Despite advances in factor VIII (FVIII) replacement and emicizumab prophylaxis, people with hemophilia A may experience breakthrough bleeding, progressive joint disease, treatment burden, and inhibitor-related limitations. Denecimig (Mim8) is a fully human, next-gene...